The University of Chicago Header Logo

Connection

Walter M. Stadler to Patient Reported Outcome Measures

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Patient Reported Outcome Measures.
Walter M. Stadler
Connection Strength
0.156
Patient Reported Outcome Measures
  1. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2020 06 01; 26(11):2506-2514.
    View in: PubMed
    Score: 0.156
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.